Peter Kang Laboratory
Peter Kang Laboratory
In our laboratory, we are developing novel targeted therapies using nanotechnology for cardiovascular diseases
Leadership
Peter Kang, MD
Dr. Kang received B.A. from University of California at Berkeley, Berkeley, CA, and M.D. from George Washington University School of Medicine, Washington, DC. He completed an Internship and Residency from Albert Einstein College of Medicine in NY, and Cardiology Fellowship from Beth Israel Hospital/Harvard Medical School, Boston, MA. He is currently a full time Cardiology faculty member at Beth Israel Deaconess Medical Center and an Associate Professor of Medicine at Harvard Medical School, Boston, MA.
Research
The major focus of our laboratory is basic and translational cardiovascular research, with an emphasis on developing novel therapies for cardiovascular diseases. One of our research interests is to study the molecular mechanisms of cardiac apoptosis, and develop novel anti-apoptotic applications in cardiovascular diseases. Specifically, we are developing novel nanoparticle-based systems that are activated by hydrogen peroxide, the most abundant form of reactive oxygen species produced during reperfusion injury, to be used in cardiovascular therapeutics and bio-imaging.
Video
